Novartis: positive study with Molecular Partners

(CercleFinance.com) - Novartis and Molecular Partners report positive top-line data from the Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19.


Novartis will exercise its option to pay 150 million Swiss francs for ensovibep under license from Molecular Partners, accelerate manufacturing scale-up and plans to seek accelerated regulatory approvals globally.

Initial results from the randomised EMPATHY Part A study in acute COVID-19 outpatients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate, against placebo achieved the primary endpoint of viral load reduction over eight days.

The secondary endpoint of COVID-19-related hospitalisation and/or emergency room visits or death showed an overall 78% reduction in the risk of ensovibep events compared to placebo.


Copyright (c) 2022 CercleFinance.com. All rights reserved.